Optimization of binding affinities in chemical space with generative pretrained transformer and deep reinforcement learning
Background: The key challenge in drug discovery is to discover novel compounds with desirable properties. Among the properties, binding affinity to a target is one of the prerequisites and usually evaluated by molecular docking or quantitative structure activity relationship (QSAR) models. Methods: In this study, we developed Simplified molecular input line entry system Generative Pretrained Transformer with Reinforcement Learning (SGPT-RL), which uses a transformer decoder as the policy network of the reinforcement learning agent to optimize the binding affinity to a target. SGPT-RL was evaluated on the Moses distribution learning benchmark and two goal-directed generation tasks, with Dopamine Receptor D2 (DRD2) and Angiotensin-Converting Enzyme 2 (ACE2) as the targets. Both QSAR model and molecular docking were implemented as the optimization goals in the tasks. The popular Reinvent method was used as the baseline for comparison. Results: The results on Moses benchmark showed that SGPT-RL learned good property distributions and generated molecules with high validity and novelty. On the two goal-directed generation tasks, both SGPT-RL and Reinvent were able to generate valid molecules with improved target scores. The SGPT-RL method achieved better results than Reinvent on the ACE2 task, where molecular docking was used as the optimization goal. Further analysis shows that SGPT-RL learned conserved scaffold patterns during exploration. Conclusions: The superior performance of SGPT-RL in the ACE2 task indicates that it can be applied to the virtual screening process where molecular docking is widely used as the criteria. Besides, the scaffold patterns learned by SGPT-RL during the exploration process can assist chemists to better design and discover novel lead candidates.
Code (1)
Tasks
Deep Reinforcement LearningDrug DiscoveryMolecular DockingMethods 이 논문이 사용한 방법론
Similar Papers 제목 키워드 기반
Guided Multi-objective Generative AI to Enhance Structure-based Drug Design
Generative AI has the potential to revolutionize drug discovery. Yet, despite recent advances in deep learning, existing models cannot generate molecules that satisfy all desired physicochemical properties. Herein, we de…
Drug DesignDrug DiscoveryStructure-aware generation of drug-like molecules
Structure-based drug design involves finding ligand molecules that exhibit structural and chemical complementarity to protein pockets. Deep generative methods have shown promise in proposing novel molecules from scratch …
Drug DesignBeyond Affinity: A Benchmark of 1D, 2D, and 3D Methods Reveals Critical Trade-offs in Structure-Based Drug Design
Currently, the field of structure-based drug design is dominated by three main types of algorithms: search-based algorithms, deep generative models, and reinforcement learning. While existing works have typically focused…
Reinforcement LearningAI Model for Predicting Binding Affinity of Antidiabetic Compounds Targeting PPAR
This study aims to develop a deep learning model for predicting the binding affinity of ligands targeting the Peroxisome Proliferator-Activated Receptor (PPAR) family, using 2D molecular descriptors. A dataset of 3,764 s…
Drug DiscoveryMolecular DockingDrugGen 2: A disease-aware language model for enhancing drug discovery
Current computational approaches for drug design typically focus on generating molecules conditioned on specific targets or general molecular properties, often neglecting the influence of disease context on target behavi…
Reinforcement LearningDrug Discovery